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a b s t r a c t
Autosomal-dominant polycystic kidney disease (ADPKD) is a relatively frequent genetic
disorder that is associated with increased prevalence of intracranial aneurysms (IAs).
However, evidence on the natural history of IAs in ADPKD is suboptimal. That leads to
difﬁculties in development of recommendations on surveillance on patients with IAs in their
medical history, or the need for repeat imaging for IAs in those with a negative result of the
initial screening. The aim of the article is to present our experience on the natural history of
IAs in ADPKD patients.
Material and methods: Thirty-four ADPKD patients, managed at our outpatient department,
with imaging for intracranial aneurysms performed at least twice, were included into
present retrospective analysis.
Results: Among 8 patients with an IA in their medical history, no new IA was observed during
93 patient-years of follow-up. In 6 patients with untreated, unruptured IAs, IA growth was
observed in 2 cases during 32 patient-years of follow-up. Finally, among 20 patients with a
negative result of initial screening, 2 new IAs were noticed during 115 patient-years of
follow-up, including 1 patient with a positive family history for an IA, and 1 patient without a
family history.
Conclusions: Our observations support repeat imaging for IAs in patients with ADPKD,
positive family history of IA, and negative result of initial screening. Additionally, efforts
should be made to develop clinical and/or laboratory risk factors for IAs development in
ADPKD patients without family history of IA, which enable to identify patients who should
undergo repeat imaging for IAs.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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some authors advocate for universal screening for IAs in
ADPKD patients [6], the screening for IAs is quite costly, and
the treatment of IAs uncovered by it is not free from the risk of
peri-procedural complications [7,8]. That is why the screening
for IAs is recommended only in selected subgroups including
high-risk patients [1,2,9]. However, in general, these recom-
mendations are not supported by large, high-quality studies.
Also, evidence on the natural history of IAs in ADPKD is
suboptimal; the knowledge on this subject is based only on a
few studies, which included less than 200 participants [3,10–
13]. That leads to difﬁculties in development of high-quality
recommendations on (1) surveillance on patients with IA/IAs
in their medical history, or (2) the need for repeat screening for
IAs in those with a negative result of the initial examination.
According to the authors of the latest review [14], further
studies on the natural history of IAs in ADPKD are needed. The
aim of the article is to present our experience on the natural
history of IAs in this group of patients.
1. Material and methods
All adult ADPKD patients, managed at our outpatient
department, with imaging for intracranial aneurysms per-
formed at least twice, were included into present retrospec-
tive analysis. Most of them (23/34, 68%) initially participated
in our cross-sectional study on the prevalence of IAs in
ADPKD patients; the design and results of that study were
published previously [15]. The follow-up examinations
were performed between July, 2009, and May, 2017. In all
participants, the diagnosis of ADPKD was established
according to current criteria [16].
In general, population of the current study may be divided
into 3 categories: (1) patients with rupture, or treatment, of
an IA in their medical history, who were screened for new
IAs, according to current recommendations [1,2]; (2) patients
with diagnosed IA, who were not qualiﬁed to surgical or
intravascular intervention, and who were reevaluated for IA
growth, according to current recommendations [2]; and (3)
patients without IA on the initial imaging. In the latter
category, imaging was made in patients with a family history
of IAs, according to current standards [1,2,9]; and in those with
symptoms suggesting the possibility of IA development (in
most cases headache), what was also in line with recommen-
dations [1,9]. Additionally, due to the previous observations
[3,15] that the frequency of IAs development in ADPKD
increases after 45 year-of-age, and according to the suggestion
of Lee at al. [9] that repeat screening should be considered in
patients with ADPKD who are at high risk of an IA 5–10 years
after the initial examination, imaging was proposed to
patients older than 45 year-of age with a negative result of
initial screening. Finally, examination for IAs was proposed
to those before renal transplantation, with uncontrolled
hypertension, and tobacco smokers, what was also in line
with guidelines [9].
In all cases, 3D time-of-ﬂight magnetic resonance angiog-
raphy (MRA) of the brain was performed. Demographic and
clinical data were extracted from case records. Renal function
was assessed according to the CKD-EPI formula.The study was conducted in accordance to the principles of
the Declaration of Helsinki. Due to the fact that examinations
were made based on medical indications, and were in line with
current guidelines, the approval of the ethics committee was
not necessary.
Descriptive statistics was made using Statistica software.
Quantitative data are expressed as mean  standard deviation.
2. Results
Thirty-four patients were included into current study, includ-
ing 8 patients with rupture (n = 7), or treatment (n = 1), of an IA
in their medical history (subgroup 1); 6 patients with
untreated, unruptured IAs, who were reevaluated for IA
growth (subgroup 2); and 20 patients with a negative result
of initial screening (subgroup 3). Characteristics of patients are
presented in Table 1.
In subgroup 1, there were 4 men (50%), and 4 women (50%).
The mean age of patients was 53.6  13.1 years (range 30–70
years). The mean estimated glomerular ﬁltration rate (eGFR)
was 49  34.5 mL/min/1.73 m2 (range 17–122 mL/min/1.73 m2).
Mean time between IA rupture, or treatment, and the last
imaging was 139  66.2 months (range 36–252 months). In this
subgroup, no new IA was noticed.
Subgroup 2 included 1 man (17%), and 5 women (83%). The
mean age in this subgroup was 62.8  2.6 years (range 60–67
years), and the mean eGFR was 45  32.6 mL/min/1.73 m2
(range 12–95 mL/min/1.73 m2). Mean time between the diag-
nosis of IA and the last imaging was 64  12.9 months (range
50–85 months). During the observation period, IAs in 4 patients
(67%) were stable, while in 2 cases (33%) growth of IAs was
noted.
Finally, in subgroup 3, there were 11 men (55%), and
9 women (45%). The mean age in this subgroup was
50.2  13.5 years (range 29–79 years), and the mean eGFR
was 56  28.7 mL/min/1.73 m2 (range 7–99 mL/min/1.73 m2).
The mean time between the ﬁrst and the last imaging was
69  15.5 months (range 36–110 months). In this subgroup,
2 new IAs in 2 patients (10%) were noted. The ﬁrst patient
with a new diagnosed IA was a 40 year-old male with a
positive family history for IA, and no symptoms, while the
second patient was a 64-year-old woman with a negative
family history for an IA, with stage 3 chronic kidney disease
(CKD), who was a tobacco smoker. She had labile values of
blood pressure and reported periodical appearance of slight
dizziness. In the former patient the interval between the
ﬁrst (negative) and the second (positive) examination was
71 months, while in the latter – 55 months.
3. Discussion
We attempted to analyze the natural history of IAs in ADPKD
based on 34 patients, divided into 3 subgroups.
In subgroup 1, screening for new IAs in those with IA
rupture, or treatment, in their medical history, was done.
According to the literature [11,17], patients with IA in their
medical history are at risk for development of new IAs.
Therefore, screening for new IAs is recommended in this group
Table 1 – Characteristics of the patients included into the study.
Pt no. Subgroup Sex Age at the
last imaging
(years)
Familial
history
of IA
Follow-up
duration
(months)
eGFR
(CKD-EPI) at the
last imaging
(mL/min/1.73 m2)
Intracranial
aneurysm
characteristics*
1 1 M 54 N 120 68 ACoA, ruptured
2 1 F 63 N 252 18 MCA, ruptured
3 1 F 30 P 36 122 ACoA, ruptured
4 1 F 70 N 156 50 ND, ruptured
5 1 F 53 P 168 51 MCA, ruptured
6 1 M 46 N 156 25 ACoA, ruptured
7 1 M 46 N 156 41 MCA, ruptured
8 1 M 67 N 67 17 ACoA, treated
9 2 F 61 N 67 60 MCA, 4 mm, stable
10 2 F 60 N 62 16 ICA, 2.5 mm ! 4 mm
11 2 M 62 N 50 95 ACeA, 2 mm, stable;
MCA, 2 mm, stable
12 2 F 65 N 52 24 ACeA, 5 mm, stable
13 2 F 67 N 70 12 MCA, 7 mm, stable
14 2 F 62 N 85 60 MCA, 2 mm ! 4 mm;
MCA, 2.5 mm ! 4 mm
15 3a F 56 N 69 27.2
16 3a F 62 N 79 60
17 3b M 40 P 71 93 MCA, 5.5 mm
18 3c M 54 N 84 15
19 3a F 55 N 79 83
20 3c M 67 N 75 11
21 3d,e F 36 N 36 94
22 3c,f F 62 N 58 7
23 3e M 36 N 54 54
24 3a M 57 N 84 74
25 3e M 32 N 73 72
26 3d,f M 40 N 71 18
27 3a M 79 N 75 40
28 3b M 38 N 68 76
29 3a F 56 N 60 71
30 3e F 45 N 50 68
31 3a,e,f F 64 N 55 48 ICA, 3 mm
32 3d,e F 29 N 61 99
33 3e M 39 N 110 68
34 3a,d,f M 56 N 67 50.9
* In subgroup 1, aneurysm location and whether it ruptured, or was prophylactically treated have been presented; in subgroup 2, aneurysm
location, and its maximum diameter have been presented in stable cases, while in those with progression aneurysm's maximum diameter
have been presented both in the initial, and the last imaging; in subgroup 3, aneurysm location and its maximum diameter have been
presented in those with positive result of the follow-up imaging.
Motive for repeat screening in patients with a negative result of the initial examination (subgroup 3): a: age >45 years; b: positive family history
for intracranial aneurysm; c: before renal transplantation; d: uncontrolled arterial hypertension; e: symptoms; f: tobacco smokers.
Abbreviations: M: male; F: female; P: positive; N: negative; ACoA: anterior communicating artery; ACeA: anterior cerebral artery; MCA: middle
cerebral artery; ICA: internal carotid artery; ND: no data.
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subgroup despite 93 patient-years of follow-up. However, this
fact may be attributed to the small number of cases in this
subgroup, and the bias associated with study design.
Subgroup 2 consisted of patients, in whom observation of
previously diagnosed IAs was conducted. Indications for
repeat imaging are the least controversial in such patients,
compared to other subgroups. In our series, 2 cases of IAs
growth was observed during 32 patient-years of follow-up. The
progression involved 33% (2/6) of our series. The incidence of
IAs growth was higher in our study (6.25%) compared to the
results of meta-analysis of Zhou et al. (1.84%) [14], and the
review of Cagnazzo et al. (0.4%) [18]. We believe that ourobservation supports the need for reevaluation in ADPKD
patients with untreated unruptured IAs. According to Chap-
man et al. [2], in this group imaging should be repeated every
6–24 months, and, based on our results, we agree with this
statement.
The last subgroup included 20 patients with a negative
result of the ﬁrst screening for IAs. The indications for repeat
examinations in such patients are relatively poorly supported
by the literature except for those with a family history of IA
rupture, or with symptoms suggestive of IA possibility. We
observed development of 2 new IAs during 115 patient-years of
follow-up. New IAs were observed in 10% (2/20) of our series,
compared to 2.6% in the study of Schrier et al. [12]. Again, the
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baseline was higher in our analysis (1.75%) compared to the
meta-analysis of Zhou et al. (0.63%) [14]. It might be caused
by the fact that patients with low risk for IAs (e.g. young,
asymptomatic, non-smokers, with a negative family history)
were not subjects for repeat screening in our center. In our
analysis, in 1 patient, a family history of IA was positive, and
this case is in line with the recommendation for repeat
imaging in such patients [1,2,9]. However, in the second case,
indications for repeat screening might be considered contro-
versial. The family history for IAs in this patient was negative,
and slight dizziness is not infrequent in this age group. She
was a tobacco smoker; however, smoking is considered a
risk factor for IAs development in the general population [19],
but it is not known if it also applies to ADPKD. This case
illustrates the need for further searching for risk factors for
IAs development, using clinical, and laboratory approach.
Until now, it is even not known whether risk factors for IAs
development in the general population apply also to ADPKD
patients. Similarly, molecular biology led to identiﬁcation of
factors that may contribute to IAs development, and may
become laboratory markers of IAs in the general population
[20]; there is a need to verify whether these factors may
become markers of IAs in ADPKD.
In contrast to the general population, where the median age
of IA rupture is around 50 years, in ADPKD the risk of IA rupture
is maximal between 40 and 50 years, and decreases after 50
years-of age [21]. The median age of IA rupture in ADPKD is
around 40 years [22]. However, due to the fact that the
prevalence of IAs increases with age [3,14], and substantial
frequency of IA progression in patients after 60 year-of-age
observed in our study (subgroup 2), we believe that even
patients older than 50 years-of-age require re-screening.
Having in mind obvious limitations of our analysis, in-
cluding relatively low number of cases, and its design, we feel
that until accurate clinical, and laboratory risk factors for IAs
development in ADPKD population are available, indications
for repeat screening in those with a negative result of the ﬁrst
study should not be narrowed.
4. Conclusions
Our observations support repeat imaging for IAs in patients
with ADPKD, positive family history of IA, and negative result
of initial screening. Additionally, efforts should be made to
develop clinical and/or laboratory risk factors for IAs deve-
lopment in ADPKD patients without family history of IA,
which enable to identify patients who should undergo repeat
screening for IAs.
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